Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AFMD |
---|---|---|
09:32 ET | 5654 | 3.51 |
09:33 ET | 111 | 3.4806 |
09:35 ET | 1170 | 3.4901 |
09:37 ET | 1000 | 3.53 |
09:42 ET | 116 | 3.54 |
09:44 ET | 500 | 3.5156 |
09:48 ET | 1000 | 3.5118 |
09:50 ET | 1000 | 3.515 |
09:51 ET | 506 | 3.48 |
09:55 ET | 3345 | 3.4506 |
09:57 ET | 3391 | 3.42 |
10:00 ET | 346 | 3.41 |
10:02 ET | 100 | 3.425 |
10:04 ET | 344 | 3.4 |
10:06 ET | 176 | 3.4042 |
10:09 ET | 615 | 3.42 |
10:20 ET | 1100 | 3.35 |
10:22 ET | 1400 | 3.37 |
10:26 ET | 2600 | 3.32 |
10:27 ET | 135 | 3.3136 |
10:29 ET | 550 | 3.33 |
10:31 ET | 926 | 3.335 |
10:36 ET | 300 | 3.35 |
10:40 ET | 100 | 3.345 |
10:42 ET | 200 | 3.37 |
10:44 ET | 4160 | 3.38 |
10:45 ET | 5065 | 3.35 |
10:47 ET | 500 | 3.36 |
10:56 ET | 100 | 3.38 |
11:03 ET | 300 | 3.35 |
11:07 ET | 100 | 3.35 |
11:12 ET | 229 | 3.35 |
11:18 ET | 750 | 3.3505 |
11:25 ET | 100 | 3.335 |
11:27 ET | 100 | 3.34 |
11:32 ET | 100 | 3.33 |
11:39 ET | 229 | 3.325 |
11:43 ET | 500 | 3.31 |
11:45 ET | 150 | 3.308 |
11:48 ET | 528 | 3.28 |
11:59 ET | 306 | 3.2797 |
12:01 ET | 200 | 3.26 |
12:06 ET | 100 | 3.265 |
12:08 ET | 229 | 3.265 |
12:12 ET | 900 | 3.27 |
12:15 ET | 229 | 3.265 |
12:21 ET | 500 | 3.2799 |
12:26 ET | 229 | 3.28 |
12:32 ET | 500 | 3.29 |
12:33 ET | 429 | 3.285 |
12:35 ET | 1000 | 3.285 |
12:39 ET | 100 | 3.289 |
12:42 ET | 218 | 3.27 |
12:46 ET | 2365 | 3.27 |
12:48 ET | 2900 | 3.255 |
12:55 ET | 2545 | 3.25 |
12:57 ET | 400 | 3.245 |
01:00 ET | 100 | 3.26 |
01:02 ET | 250 | 3.25 |
01:04 ET | 100 | 3.22 |
01:08 ET | 600 | 3.22 |
01:11 ET | 200 | 3.205 |
01:13 ET | 800 | 3.2131 |
01:15 ET | 200 | 3.18 |
01:18 ET | 500 | 3.21 |
01:22 ET | 450 | 3.205 |
01:24 ET | 900 | 3.205 |
01:26 ET | 400 | 3.205 |
01:31 ET | 6211 | 3.2 |
01:33 ET | 2020 | 3.2097 |
01:36 ET | 116 | 3.18 |
01:42 ET | 454 | 3.19 |
01:54 ET | 100 | 3.19 |
01:56 ET | 200 | 3.185 |
01:58 ET | 1853 | 3.1798 |
02:00 ET | 2000 | 3.1704 |
02:03 ET | 1600 | 3.18 |
02:05 ET | 1100 | 3.17 |
02:12 ET | 400 | 3.19 |
02:20 ET | 2000 | 3.1852 |
02:21 ET | 2334 | 3.19 |
02:23 ET | 1200 | 3.175 |
02:34 ET | 100 | 3.17 |
02:39 ET | 796 | 3.15 |
02:41 ET | 700 | 3.148 |
02:56 ET | 1400 | 3.17 |
02:57 ET | 2000 | 3.1501 |
02:59 ET | 2300 | 3.18 |
03:01 ET | 2000 | 3.1401 |
03:12 ET | 3098 | 3.2 |
03:17 ET | 177 | 3.1803 |
03:21 ET | 100 | 3.19 |
03:28 ET | 1757 | 3.16 |
03:30 ET | 244 | 3.16 |
03:33 ET | 100 | 3.17 |
03:37 ET | 1372 | 3.1699 |
03:39 ET | 1340 | 3.17 |
03:44 ET | 100 | 3.18 |
03:50 ET | 200 | 3.15 |
03:55 ET | 100 | 3.1504 |
03:57 ET | 1116 | 3.15 |
04:00 ET | 884 | 3.16 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Affimed NV | 48.1M | -0.7x | --- |
Collplant Biotechnologies Ltd | 47.5M | -2.7x | --- |
Atara Biotherapeutics Inc | 64.2M | -0.4x | --- |
Kronos Bio Inc | 51.2M | -0.5x | --- |
LAVA Therapeutics NV | 42.9M | -1.8x | --- |
Curis Inc | 31.6M | -0.5x | --- |
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $48.1M |
---|---|
Revenue (TTM) | $929.5K |
Shares Outstanding | 15.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.11 |
EPS | $-4.84 |
Book Value | $4.10 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 51.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -8,005.25% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.